PSG Global Site Network Map

Learn more about our fully integrated global site network that can support your molecule from development to commercialization. ...View More

Introducing Pharma Services, the leader in Drug Development, Trial Logistics and Manufacturing

Patheon has been aquired by Thermo Fisher Scientific, to create Pharma Services, the leader in Drug Development, Clinical Trial Logistics & Manufacturing. See full combined capabilities that are now offered by Patheon! ...View More

Patheon OneSource Information Sheet

Take months off the development timelines of your large and small molecule discoveries. With Patheon OneSource™ you can combine your drug substance and drug product development and manufacturing into a single customized solution to simplify your supply chain and accelerate your discovery to proof of concept. ...View More

Patheon Overview Brochure

Patheon is transforming the way pharmaceuticals are made with a simplified, end-to-end supply chain for pharmaceutical and biopharmaceutical companies of all sizes. Drug substances and drug products. Development and manufacturing. Small and large molecules. Sterile, oral solid and softgel dosage forms. Patheon offers a comprehensive range of services spanning all phases and scales that is wider and deeper than any other CDMO. ...View More

Biologics Fact Sheet

The challenges, risks and costs of bringing complex large molecule products to market are growing exponentially. Gaining a competitive advantage is more difficult. Drawing on 20 years of biologic experience, Thermo Fisher Scientific offers you flexible, end-to-end solutions and expertise in development and manufacturing combined with advanced technical capabilities. ...View More

Quick to Clinic™ Delivers Phase I Clinical Trial Material, Fast

The pressure to file an IND makes accelerated Phase I safety testing a priority. With the Quick to Clinic program, Thermo Fisher Scientific can deliver your large molecule drug substance for First-in-Human studies in as little as 12 months. Now you can meet important milestones – such as filing the IND – or secure additional funding with all the confidence your project needs and, we can supply. Because helping you reduce the time it takes to get your discovery to the patients who need it matters, our Quick to Clinic for Biologics is made with speed and flexibility. ...View More

Biologics & Flexible Biomanufacturing Overview Brochure

Your molecule has the power to change lives and shape the future. Patheon is the company that offers you the agility and speed to help you get there ahead of schedule while maintaining the highest quality. We bring deep scientific expertise to every challenge and our proven track record of scaling up biologics help ensure you gain cost and time savings at every stage of the biologic development process. ...View More

API (Small Molecule) Information Sheet

With Patheon you’ll have access to a vast array of small molecule API capabilities in Europe and the United States. Reactors ranging from 30 L up to 16 m3, comprehensive analytical services and expertise in all the chemistries you expect, as well as many unique solutions and innovative technologies you won’t find anywhere else. We deliver high-quality API via a seamlessly scalable process that will rapidly achieve your goals at each phase of development while laying a sound foundation for your future success. ...View More

Florence, SC (East) Site Flyer

Our new state-of-the-art API manufacturing facility in Florence, South Carolina is the latest addition to our robust network of development and manufacturing sites. In its production space, Florence East features reactors ranging from 50-11,000 liters producing multiple products simultaneously. ...View More

Quick to Clinic Information Sheet

Phase I clinical materials in as little as 12 weeks. Only twelve weeks from receipt of your API, Patheon Quick to Clinic™ can deliver bulk clinical trial materials for first-in-human studies. That includes a one-month stability study so you have all the data you need to make informed proof of concept decisions and complete regulatory submissions. What’s more, this accelerated program gives you the choice of five dosage forms. ...View More

Case Study - Collegium Pharmaceutical’s Approach to Abuse Deterrence Breaks New Ground

The opioid abuse epidemic is a serious public health crisis that demands action on the part of many stakeholders. While abuse-deterrent opioids will not solve the opioid abuse epidemic alone, they play a critical role in the fight against it. While Collegium had come up with an innovative new approach to abuse deterrent formulations, it did not have the capacity or resources to manufacture its drug on a commercial scale. This case study discusses how Collegium Pharmaceutical partnered with Patheon to solve the needed space and expertise necessary to run this unique platform to develop a product that did not fit into the traditional manufacturing mold. ...View More

Video Case Study - Curbing the Opioid Epidemic with Pacira Pharmaceuticals

Author: Rich Whitworth, Content Director, The Medicine Maker Steve McCairns, Executive Director of UK Operations, Pacira Pharmaceuticals
Pacira Pharmaceuticals is working to curb the opioid epidemic with its injectable suspension, EXPAREL®. EXPAREL is produced at Patheon’s Swindon facility, creating a strategic partnership between the two companies. ...View More

Case Study – Fighting The Opioid Epidemic: How Grünenthal’s Abuse-Deterrent Technology Contributes

As part of the FDA's efforts to address opioid addiction, the agency put an opioid action plan into effect in 2011 to "reduce opioid abuse, dependence, and overdose in the United States." Part of this plan included a call to pharmaceutical manufacturers to develop and expand access to abuse-deterrent formulations (ADFs) in order to discourage abuse among patients and promote innovation in the industry. ...View More

Case Study - How Pacira Pharma Is Working To Help Curb The Opioid Epidemic

Poorly managed postoperative pain can have a significant impact on a patient’s recovery. Consequently, more patients relying in opioids furthers compounds the opioid epidemic. This case study discusses how Patheon and Pacira Pharma partnered to help curb this epidemic. ...View More

Solid and Sterile Dose Form Brochure

Access a remarkable range of conventional and specialized oral solid dosage form capabilities and scale. Tap the many clinical and technical advantages of softgels with a host of patent-protected specialized technologies. Access Extensive sterile pharmaceutical development and manufacturing capabilities at all scales. ...View More

Early Development Fact Sheet

Whether your company is built on a single molecule or you’re a global pharmaceutical leader, you need fast, cost-effective and scientifically-based insights during early-phase development. Patheon can provide you with customized early development strategies and technical solutions to solve complex development challenges. ...View More

Softgel Innovation and Unique OTC Solution

Learn about Patheon's full dose form capabilities and technologies, including various tablets, caplets, chewables, powders, softgels, and more. ...View More

Benefits of Addressing Solubility Earlier in Development

With up to 90% of today’s new molecular entities presenting as insoluble, not addressing solubility challenges early can result in even greater delays – and potentially compound failure. Patheon Solubility Enhancement Services approaches solubility a fundamentally different way by addressing low solubility earlier in development and identifying the technologies most likely to work before you get started. ...View More

Solubility Enhancement Services Information Sheet

Not addressing solubility at the beginning of development can put your timeline and your molecule at risk. As many as 60-90% of drug candidates have bioavailability challenges and 37% will fail in phase I-III clinical trials as a result. ...View More

Infographic - A Tale of Two Molecules

What’s the best path for your low soluble molecule? Two molecules, both designed to treat the same condition, both with solubility challenges. Two biopharma companies racing to be first. Biopharma A chooses to move into trials as quickly as possible, while Biopharma B decides to address broader solubility concerns first. Who gets to market first may surprise you. ...View More

The Increasing Risks of Waiting to Address Solubility

Under pressure to minimize costs and timelines during clinical development, it’s become common to put off solubility challenges. However, with 60%–90% of today’s new molecular entities presenting as insoluble, it makes sense to reconsider this strategy and its significant risks. ...View More

Looking for Solutions?

We can help.